1
0
• Department of Pharmaceuticals Secretary Shri Manoj Joshi visits Amneal Pharmaceuticals in Ahmedabad
• Visit highlights Amneal’s contributions to pharmaceutical manufacturing and innovation in India
• Company shares its capabilities across R&D, complex medicines and biosimilars following the acquisition of Kashiv Biosciences
• Discussion explores opportunities for industry, academia and government to support biopharmaceutical innovation and workforce development ¡¡
Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, Government of India, visited Amneal Pharmaceuticals’ corporate office in Ahmedabad on Tuesday and met with company leaders to discuss Amneal’s growth, investments, pipeline and expanding capabilities.
The discussions covered Amneal’s contribution to pharmaceutical manufacturing and innovation and its expanded biosimilars capabilities following the acquisition of Kashiv BioSciences.The discussions highlighted Amneal’s growing contribution to India’s pharmaceutical ecosystem through its manufacturing footprint, investments in advanced manufacturing and R&D and capabilities across complex generics, injectables, peptides and APIs. Amneal also shared an overview of its diversified global manufacturing expertise, innovation capabilities, partnerships and its role in supporting global pharmaceutical supply chains.
Amneal’s recent acquisition of Kashiv BioSciences has further strengthened these capabilities, creating a fully integrated global biosimilars platform spanning research, development, manufacturing and commercialisation.
The combination brings together Kashiv’s biologics capabilities with Amneal’s commercial and manufacturing scale, expanding the company’s biosimilars pipeline and positioning the business for long-term growth.The visit also included a discussion of India’s opportunity to build on its pharmaceutical manufacturing capabilities and advance biopharmaceutical innovation, including through greater investment in R&D, innovation capital, advanced infrastructure, industry-academia collaboration and regulatory science.
These priorities are reflected in the Government’s proposed Biopharma SHAKTI programme, with an outlay of ₹10,000 crore over five years to elevate India’s biopharmaceutical ecosystem.Dr. Parva Purohit, Senior Vice President and Head R&D, Amneal Pharmaceuticals, said, “India has a strong foundation in pharmaceutical manufacturing and now has an opportunity to add greater depth in biopharmaceutical innovation.
At Amneal, we remain committed to building capabilities across manufacturing, R&D, biosimilars and complex medicines.”Mr Rahul Maitra, Senior VP, Human Resources, Amneal, added, “We are encouraged by Mr Manoj Joshi’s visit and the productive discussion towards skill development efforts that are underway within the existing government schemes.
Pharmaceuticals industry in India is growing rapidly, both in terms of R&D as well as manufacturing. Hence it is important that equal emphasis is laid on industry-academia- government collaborations to attain trained and industry-ready workforce.”During the visit, Amneal leaders and Secretary Manoj Joshi discussed the company’s investments and growing capabilities across manufacturing, R&D, biosimilars and complex medicines.
The discussion also covered the challenges and enablers for biopharmaceutical growth, including innovation capital, advanced research infrastructure, industry-academia-government collaboration and regulatory science.The interaction reinforced the importance of continued government-industry collaboration to strengthen India’s biopharmaceutical capabilities, advance innovation and support investment in advanced manufacturing.
About AmnealAmneal is expanding access to safe, effective, and affordable medicines. Our difference is the precision and scale of a world-class biopharmaceutical company, matched with the heart of a team that cares deeply, knowing every dose we deliver can impact people’s lives.
Brothers and co-CEOs Chirag and Chintu Patel founded Amneal in 2002 as a promise rooted in access: to deliver needed medicines to families like their own. Today, we have grown our portfolio to approximately 300 generic, biosimilar, and specialty medicines, delivering more than 160 million prescriptions each year across a broad range of therapeutic areas.With an industry-leading track record, our focus on quality is unwavering. We continue to deepen our investment in high-quality, reliable manufacturing, including domestic production, to help ensure communities receive the care they need and deserve. By taking on complex and high-barrier medicines, we’re reimagining what’s possible to make access more sustainable across the healthcare system.We’re Amneal. And we’re reimagining what’s possible to make medicine accessible for all.
Media contactsT
anushree Roy Chowdhury Head – Corporate Communications, Amneal Pharmaceuticals
tanushree.chowdhury@amneal.com 99994 25750
